1. Home
  2. DVAX vs ETV Comparison

DVAX vs ETV Comparison

Compare DVAX & ETV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVAX
  • ETV
  • Stock Information
  • Founded
  • DVAX 1996
  • ETV 2005
  • Country
  • DVAX United States
  • ETV United States
  • Employees
  • DVAX N/A
  • ETV N/A
  • Industry
  • DVAX Biotechnology: Pharmaceutical Preparations
  • ETV Investment Managers
  • Sector
  • DVAX Health Care
  • ETV Finance
  • Exchange
  • DVAX Nasdaq
  • ETV Nasdaq
  • Market Cap
  • DVAX 1.7B
  • ETV 1.7B
  • IPO Year
  • DVAX 2004
  • ETV N/A
  • Fundamental
  • Price
  • DVAX $12.90
  • ETV $14.40
  • Analyst Decision
  • DVAX Buy
  • ETV
  • Analyst Count
  • DVAX 2
  • ETV 0
  • Target Price
  • DVAX $22.00
  • ETV N/A
  • AVG Volume (30 Days)
  • DVAX 1.3M
  • ETV 252.5K
  • Earning Date
  • DVAX 11-07-2024
  • ETV 01-01-0001
  • Dividend Yield
  • DVAX N/A
  • ETV 8.75%
  • EPS Growth
  • DVAX N/A
  • ETV N/A
  • EPS
  • DVAX 0.15
  • ETV N/A
  • Revenue
  • DVAX $260,810,000.00
  • ETV N/A
  • Revenue This Year
  • DVAX $21.64
  • ETV N/A
  • Revenue Next Year
  • DVAX $19.81
  • ETV N/A
  • P/E Ratio
  • DVAX $85.33
  • ETV N/A
  • Revenue Growth
  • DVAX N/A
  • ETV N/A
  • 52 Week Low
  • DVAX $9.74
  • ETV $11.05
  • 52 Week High
  • DVAX $15.01
  • ETV $13.50
  • Technical
  • Relative Strength Index (RSI)
  • DVAX 57.32
  • ETV 55.62
  • Support Level
  • DVAX $12.66
  • ETV $14.36
  • Resistance Level
  • DVAX $13.17
  • ETV $14.63
  • Average True Range (ATR)
  • DVAX 0.29
  • ETV 0.13
  • MACD
  • DVAX -0.04
  • ETV -0.02
  • Stochastic Oscillator
  • DVAX 48.08
  • ETV 51.06

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.

Share on Social Networks: